To the Editor, While treatment of relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL) remains a significant challenge, those with T-cell ALL (T-ALL) have particularly poor outcomes. Patients with R/R T-ALL and T-cell lymphoblastic lymphoma (T-LBL) have a median overall survival (mOS) of approximately 6 months.1 Nelarabine is the only Food and Drug Administration (FDA) approved therapy for R/R T-ALL.
Miles Thomas
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Miles
Contact Miles, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack